


II. AMENDMENTS TO THE CLAIMS


Claims 1-7. (Canceled)

Claim 8. (Currently Amended) ~~Compounds according to any one of claims 1-3, selected from the group consisting of:~~


Budesonide 21-(4'-nitrooxymethyl)benzoate:




~~Budesonide 21-[2-[6-(nitrooxymethyl)-2-pyridinyl]acetate]~~



~~Budesonide 21-[2-[4-[3-(nitrooxy)propyl]-1-piperazinyl]acetate]~~



Budesonide-21[2-[4-[2-[4-nitrooxymethyl)benzoyloxy]ethyl]-1-piperazinyl]acetate]



Claim 9. (Withdrawn) Use of the compounds according to claim 1, for the preparation of medicaments.

Claim 10. (Withdrawn) Use of the compounds according to claim 1, as drugs having antiinflammatory activity at peripheral level.

Claim 11. (Withdrawn) Use of the compounds according to claim 1, for the therapy of neurodegenerative diseases on an inflammatory and traumatic basis of the nervous system.

Claim 12. (Withdrawn) Use of the compounds according to claim 1, as drugs having an antiarthritic activity.

Claim 13. (Withdrawn) Use of the compounds of claim 1, as drugs having an immunodepressive activity.

Claim 14. (Withdrawn) Use of the compounds according to claim 1, as drugs having an angiostatic/angiogenetic activity.

Claim 15. (Withdrawn) Use of the compounds according to claim 1, as drugs having an antiasthmatic activity.

Claim 16. (Withdrawn) Use of the compounds according to claim 1, in substitutive hormonal therapies, preferably in the post-menopause therapy.

Claim 17. (Withdrawn) Use of the compounds according to claim 1, in rheumatic disease therapies.

Claim 18. (Withdrawn) Use of the compounds according to claim 1, in renal disease therapies.

Claim 19. (Withdrawn) Use of the compounds according to claim 1, in bronchial disease therapies.

Claim 20. (Withdrawn) Use of the compounds according to claim 1, in ocular disease therapies.

Claim 21. (Withdrawn) Use of the compounds according to claim 1, in dermatologic disease therapies.

Claim 22. (Withdrawn) Use of the compounds according to claim 1, in autoimmune disease therapies.

Claim 23. (Withdrawn) Use of the compounds according to claim 1, in tumoral process therapies, optionally in combination with chemotherapeutic and/or radiotherapeutic treatments.

Claim 24. (Withdrawn) Use according to claim 10, in inflammatory pathologies affecting the gastrointestinal system.

Claim 25. (Withdrawn) Use of the compounds according to claim 1, wherein the glucocorticoid compounds are used in respiratory pathologies characterized by broncho-obstructive events.

Claim 26. (Currently Amended) A pharmaceutical composition comprising a compound according to claim [[1]] 8 and a pharmaceutically acceptable carrier.